Description: This article discusses the utilization of credibility concepts to reinsurer-cedant moratality analysis.

Description: Highlights of the 1999 Manulife/SOA annual large amount/older age mortality study

Description: This article lists participating companies and countries with the International Experience Study and describes the process of adding additional countries to the study.

Description: The article discovers that mortality is higher for females than for males at higher ages, and suggests "stress" as the explanation. It then discusses mental illness research, including recovery therefrom.

Description: This article is based on a recent high face amount mortality study completed for the SOA. The data was derived from the Milliman Industry Mortality Study and Analysis (MIMSA), a recent comprehensive life insurance industry study of mortality and lapse. There were a number of interesting findings in the high face amount study, several of which are discussed in this article.

Description: This article talks about longevity risk and reinsurance and its global challenges.

Description: Discussion of the latest report of the Individual Life Experience Committee ILEC Mortality for Standard Individually Underwritten Life Insurance Between 2005 and 2007 Policy Anniversaries.

Description: This article describes some of the drawbacks to the assessment of longevity risk adopted by most practitioners within the UK together with an initiative that provides a platform for an alternative approach that is both (a) more forward-looking in nature and (b) can complement current practices.

Description: A recent Society of Actuaries study calculates safety and stability for current Long Term Care Insurance premiums.

Description: Pricing longevity swap reinsurance transactions consists of a number of different actuarial tasks, each of which hides potential pitfalls. The article outlines the pricing process, which includes a detailed analysis of current mortality experience of the portfolio to be transferred, choice and calibration of an appropriate model for mortality improvement trends and the calculation of a risk margin which reflects the uncertainty associated with the pricing best-estimate, which includes mis-estimation risk, model risk, longevity basis risk and stochastic uncertainty.